NCT00114218View on ClinicalTrials.gov

Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

July 31, 2010

Conditions
Recurrent Uterine Corpus SarcomaUterine Carcinosarcoma
Interventions
DRUG

Gemcitabine Hydrochloride

Given IV

DRUG

Docetaxel

Given IV

Trial Locations (1)

19103

Gynecologic Oncology Group, Philadelphia

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Gynecologic Oncology Group

NETWORK

NCT00114218 - Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer | Biotech Hunter | Biotech Hunter